NIKKEI 225
38,658.17 -197.20 (-0.51%) HANG SENG
18,541.01 -280.15 (-1.49%) CRUDE OIL
80.13 +0.30 (+0.38%) GOLD FUTURES
2,358.70 +2.20 (+0.09%) DOW
38,852.86 -216.74 (-0.55%) Bitcoin GBP
53,821.91 +654.28 (+1.23%)
UCB SA (UCB.BR)
- PR Newswire
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 This article represents the primary publication of BIMZELX data from the two pivotal Phase 3 HS studies. HS is one of the most burdensome, chronic, systemic, inflammatory s
- GuruFocus.com
UCB SA's Dividend Analysis
UCB SA (UCBJY) recently announced a dividend of $0.73 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into UCB SA's dividend performance and assess its sustainability.
- PR Newswire
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
